Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check2 days agoChange DetectedThe page's revision label was updated from v3.6.6 to v3.7.0, indicating a routine update to the site or document version.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page footer now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe page's revision metadata was updated from v3.6.4 to v3.6.5, indicating a minor update to the page.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page’s revision tag was updated to a newer version, indicating a small update to the study record’s metadata. This does not modify the study details or visible content.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page now shows a new revision number (v3.6.3) replacing the previous v3.6.2, indicating a page update. This update does not alter study content or eligibility criteria.SummaryDifference0.0%

- Check80 days agoChange DetectedThe page revision tag changed from v3.6.0 to v3.6.2, signaling a newer build/version of the page. This reflects an update to the page infrastructure rather than alterations to study content.SummaryDifference0.0%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.